

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



**Europäisches
Patentamt**

**European
Patent Office**

**Office européen
des brevets**

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European-patent-application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03007071.8

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

THIS PAGE BLANK (USPTO)



Anmeldung Nr:
Application no.: 03007071.8
Demande no:

Anmeldetag:
Date of filing: 27.03.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Pharmaceutical composition of antiviral agents

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A61K31/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT SE SI SK TR LI

THIS PAGE BLANK (USPTO)

Boehringer Ingelheim International GmbH
55216 Ingelheim

Case 1-1479
Priotext

1

PHARMACEUTICAL COMPOSITION OF ANTIVIRAL AGENTS

FIELD OF THE INVENTION

The present invention relates to a pharmaceutical composition
5 useful for the treatment of viral infections comprising a
compound of the formula (I) and at least one antivirally
active compound of the formula (II). Furthermore the present
invention relates to a use of a compound of the formula (I) in
combination or alternation with a compound of the formula (II)
10 in the prophylaxis or treatment of a viral infection in a
patient. The present invention also relates to a use of a
compound of the formula (I) in combination with a compound of
the formula (II) for the manufacture of a medicament for the
prophylaxis or treatment of a viral infection in a patient. In
15 addition the present invention relates to a kit of parts and
to a manufacture for the prophylaxis or treatment of a viral
infection in a patient.

20 BACKGROUND OF THE INVENTION

Human immunodeficiency virus (HIV) is recognized as the
causative agent in AIDS.

Current therapies for HIV infection focus on inhibiting the
25 activity of viral enzymes which are essential to the life
cycle of the virus. The agents that are presently in use fall
mainly into three classes, designated Nucleoside Reverse
Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse
Transcriptase Inhibitors (NNRTIs), and Protease Inhibitors
30 (PIs). Presently, combination therapies, i.e. the selection of
two or more antiretroviral agents taken together to make up a
"drug cocktail," are the preferred treatment for HIV
infection. Combination therapies have been shown to reduce the

- 2 -


incidence of opportunistic infections and to increase survival time. Typically, the drug cocktail combines drugs from different classes, so as to attack the virus at several stages in the replication process. This approach has been shown to
5 reduce the likelihood of the development of virus forms that are resistant to a given drug or class of drugs.

Treatment failure with rebound of the amount of HIV which can be measured in the blood is common for patients treated with
10 combination antiretroviral regimens. Resistance to the drugs in the drug regimen develops as the virus replicates in the presence of these drugs. Because of structural similarities of the drugs within an antiretroviral class, cross resistance is commonly seen to the other members of that class (for example
15 virologic failure on a regimen containing an NNRTI will lead to cross resistance to the other first generation NNRTI agents). As patients experience repeated virologic failure on antiretroviral combination therapy, their viruses develop broad multi-class antiretroviral drug resistance which limits
20 the effectiveness of the next round of antiretroviral therapy. Many highly treatment experienced patients have been exposed to all three classes of antiretroviral drugs and cannot obtain two active drugs to form the core of a new, effective antiretroviral drug regimen.

25


- 3 -

Compounds of the general formula I:



wherein


- R² is selected from the group consisting of H, F, Cl, C₁₋₄ alkyl, C₃₋₄ cycloalkyl and CF₃;
- R⁴ is H or Me;
- R⁵ is H, Me or Et;
- R¹¹ is Me, Et, cyclopropyl, propyl, isopropyl, or cyclobutyl;
- Q is selected from the group consisting of:



or a pharmaceutically acceptable salt thereof, are described in the WO 01/96338 as showing activity against HIV-1 reverse transcriptase and thus being useful in the treatment of AIDS, ARC and related disorders associated with HIV-1 infection.

- 4 -

Furthermore compounds of the formula (II)




- wherein Base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and
- 5 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof, are described in the WO 88/00050 and WO 91/01137 for the therapeutic and prophylactic control and treatment of AIDS, HIV infections, hepatitis B virus (HBV) infections and retrovirus infections in animals and man. These
- 10 nucleoside compounds are transformed by cells or enzymes to triphosphates which inhibit the reverse transcriptase of retrovirus as well as the activity of DNA dependent polymerase of hepatitis B virus:
- 15 Combinations of a compound of the formula (I) with at least one compound of the formula (II) which exhibit potent therapeutic activity against HIV and HBV would greatly aid in the development of new combination therapy against human retroviral (HRV) infections and HBV.

- 5 -

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a novel pharmaceutical composition useful for the treatment or prophylaxis of viral infections comprising a compound of the
5 formula (I)



I

wherein


R² is selected from the group consisting of H, F, Cl, C₁₋₄ alkyl, C₃₋₄ cycloalkyl and CF₃;

10 R⁴ is H or Me;

R⁵ is H, Me or Et,

R¹¹ is Me, Et, cyclopropyl, propyl, isopropyl, or cyclobutyl;


Q is selected from the group consisting of:



15 or a pharmaceutically acceptable salt thereof;

- 6 -

and at least one antivirally active compound of the formula (II)



II

wherein Base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or prodrug thereof.

The pharmaceutical compositions of the present invention are useful in therapy, in particular as antivirals, especially in the treatment or prophylaxis of human retroviral (HRV) infections.

In a second aspect, there is provided a use of a compound of the formula (I), as defined hereinbefore and hereinafter, in combination or alternation with at least one antiviral active compound of the formula (II), as defined hereinbefore and hereinafter, in the prophylaxis or treatment of a viral infection in a patient.

20

In a third aspect, there is provided a use of a compound of the formula (I), as defined hereinbefore and hereinafter, in combination with at least one antivirally active compound of the formula (II), as defined hereinbefore and hereinafter, for the manufacture of a medicament for the prophylaxis or treatment of a viral infection in a patient.

25

- 7 -

In a fourth aspect of this invention, there is provided a kit of parts for the prophylaxis or treatment of a viral infection in a patient, comprising

(a) a first containment containing a pharmaceutical composition comprising a compound of the formula (I), as defined hereinbefore and hereinafter, and at least one pharmaceutically acceptable carrier, and

(b) a second containment containing a pharmaceutical composition comprising an antiviral active compound of the formula (II), as defined hereinbefore and hereinafter, and at least one pharmaceutically acceptable carrier.

In a fifth aspect of this invention, there is provided a manufacture comprising a compound of the formula (I), as defined hereinbefore and hereinafter, and at least one antiviral active compound of the formula (II), as defined hereinbefore and hereinafter, for use in combination or alternation in the prophylaxis or treatment of a viral infection in patient.

20

With the combination of a compound of the formula (I) and a compound of the formula (II) according to this invention, including its use in prophylaxis and treatment, the person skilled in the art can achieve an advantageous therapeutic effect to inhibit viral replication, especially of human retrovirus (HRV) and HBV, in particular of multiresistant HIV. In most cases, the enhanced therapeutic effect is not attainable by administration of either agent alone. In a preferred but not necessary embodiment, the effect of administration of a compound of the formula (I) and a compound of the formula (II) in combination or alternation is synergistic. Even though a combination exhibits additive and

- 8 -

not synergistic effects, the combination can still provide an effect that is different from the separate administration of the two agents. For example, the biodistribution, pharmacokinetics, cytotoxic effects or metabolism of one can be affected by the other.

Further aspects of the present invention become apparent to the one skilled in the art from the following detailed description and examples.

10

DEFINITIONS

The term "compound of the formula (I)" also comprises the pharmaceutically acceptable salts thereof.

15 The term "compound of the formula (II)" also comprises the pharmaceutically acceptable salts and prodrugs thereof.

The term "pharmaceutically acceptable salt" means a salt of the corresponding compound which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, generally water or oil-soluble or dispersible, and effective for their intended use.

25 The term includes pharmaceutically-acceptable acid addition salts and pharmaceutically-acceptable base addition salts. Lists of suitable salts are found in, e.g., S.M. Birge et al., J. Pharm. Sci., 1977, 66, pp. 1-19, which is hereby incorporated by reference in its entirety.

30

As used herein, the term "C₁₋₄ alkyl" is intended to mean linear or branched alkyl radicals containing from one to four

- 9 -

carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, sec-butyl and tert-butyl. The abbreviations Me and Et designate methyl and ethyl, respectively.

- 5 As used herein, the term "C₃₋₄ cycloalkyl" is intended to mean saturated cyclic hydrocarbon radicals containing three to four carbon atoms and includes cyclopropyl and cyclobutyl.

- 10 As used herein, the term "treatment" means the administration of the antivirally active compounds according to this invention in combination or alternation according to the present invention to alleviate or eliminate symptoms of the viral infection and/or to reduce viral load in a patient.

- 15 As used herein, the term "prevention" or "prophylaxis" means the administration of the antivirally active compounds according to this invention in combination or alternation according to the present invention post-exposure of the individual to the virus but before the appearance of symptoms
20 of the disease, and/or prior to the detection of the virus in the blood.

- As used herein, the term "human retrovirus" (HRV) includes human immunodeficiency virus type I, human immunodeficiency
25 virus type II, or strains thereof, as well as human T cell leukemia virus 1 and 2 (HTLV-1 and HTLV-2) or strains apparent to one skilled in the art, which belong to the same or related viral families and which create similar physiological effects in humans as various human retroviruses.

30

- 10 -

DETAILED DESCRIPTION OF THE INVENTION

The virally active agents according to this invention may be in either free form or in protected form at one or more of the remaining (not previously protected) carboxyl, amino, hydroxy,
5 or other reactive groups. The protecting groups may be any of those known in the art. Furthermore, the virally active agents according to this invention may also be used as in form of their pharmacologically acceptable salts and/or hydrates.

10 According to the first aspect of this invention, there is provided a novel pharmaceutical composition useful for the treatment of viral infections comprising a compound of the formula (I) and at least one compound of the formula (II).

15 According to a preferred embodiment, compounds of the invention are defined according formula (I) wherein R^2 is preferably Cl, F, or H. More preferably, R^2 is Cl or H. Most preferably, R^2 is H.

20 According to a preferred embodiment, compounds of the invention are defined according formula (I) wherein R^4 is preferably H.


According to an alternative embodiment, compounds of the
25 invention are defined according formula (I) wherein preferably R^5 is Me.

Preferably, compounds of the invention are defined according formula (I) wherein R^{11} is Et or cyclopropyl. More preferably,
30 R^{11} is Et.


According to a preferred embodiment, compounds of the

- 11 -


invention are defined according formula (I) wherein Q is preferably selected from the group consisting of:




5 More preferably, Q is:



Alternatively, preferred embodiments of the invention include compounds selected from the group consisting of:




10




15 The following known compounds constitute part of the invention as preferred compounds of the formula (II) to be combined with a compound of the formula (I):


- 12 -



3'-deoxy-3'-fluorothymidine (FLT)




2',3'-dideoxy-3'-fluorocytidine



2',3'-dideoxy-3'-fluoroadenosine

- 13 -



2',3'-dideoxy-3'-fluoroguanosine
(FLG)

including pharmaceutically acceptable salts and prodrugs of the compounds listed above.

- 5 The most preferred compound of the formula (II) to be combined with a compound of the formula (I) according to the aspects of this invention is 3'-deoxy-3'-fluorothymidine.

10 Therefore, a preferred pharmaceutical composition useful for the treatment of viral infections comprises a compound of the formula (I) and 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

15 Furthermore, a compound of the formula (I) in combination or alternation with preferably 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof, is used in the prophylaxis or treatment of a viral infection in a patient.

20 Also preferred is the use of a compound of the formula (I) in combination with 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof, for the manufacture of a medicament for the prophylaxis or treatment of a viral infection in a patient.

- 14 -

A preferred kit of parts for the prophylaxis or treatment of a viral infection in a patient, comprises

- (a) a first containment containing a pharmaceutical composition comprising a compound of the formula (I) and a pharmaceutically acceptable carrier, and
- (b) a second containment containing a pharmaceutical composition comprising 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.

A preferred manufacture comprises a compound of the formula (I) and 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof, for use in combination or alternation in the prophylaxis or treatment of a viral infection in a patient.

The advantageous effects of the combination of a compound of the formula (I) and the compound of the formula (II) are realized over a wide ratio, like for example in a ratio of between 1:250 to 250:1.

Therefore, in the compositions, combinations, kit of parts, manufacture and/or the use of the combinations according to this invention, a compound of the formula (I) and the at least one compound of the formula (II), which is preferably 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof, are preferably present in a synergistic ratio. Usually, this ratio is between about 1:250 to about 250:1. More preferably the ratio is between about 1:50 to about 50:1. The most preferred ratio is between about 1:20 to about 20:1, which includes the ratios 1:18, 1:16,

- 15 -

1:14, 1:12, 1:10; 1:8; 1:6; 1:5; 1:4; 1:3; 1:2,5; 1:2; 1:1,5;
1:1,2; 1:1; 1,2:1; 1,5:1; 2:1; 2,5:1; 3:1; 4:1; 5:1; 6:1; 8:1;
10:1, 12:1, 14:1, 16:1, 18:1 and all ranges in between. If a
further therapeutic agent is added, ratios will be adjusted
5 accordingly.

It will be appreciated that the amount of pharmaceutical
composition according to the invention required for use in
treatment or prophylaxis will vary not only with the
10 particular compound selected but also with the route of
administration, the nature and severity of the condition for
which treatment or prophylaxis is required, the age, weight
and condition of the patient, concomitant medication and will
be ultimately at the discretion of the attendant physician or
15 veterinarian. In general however the active compounds are
included in the pharmaceutically acceptable carrier in an
amount sufficient to deliver to a patient a therapeutically
effective amount of compound to inhibit viral replication in
vivo, especially HIV replication, without causing serious
20 toxic effects in the treated patient. By "inhibitory amount"
is meant an amount of active ingredient sufficient to exert an
inhibitory effect as measured by, for example, an assay such
as the ones described herein. A suitable dose will preferably
be in the range of from about 0.05 to about 200 mg/kg of body
25 weight per day.

The desired dose may conveniently be presented in a single
dose or as divided dose administered at appropriate
intervals, for example as two, three, four or more doses
30 per day.

The pharmaceutical composition according to the present

- 16 -

invention is conveniently administered in unit dosage form; for example containing 5 to 3000 mg, conveniently 5 to 1000 mg of active ingredient(s) per unit dosage form.

- 5 The pharmaceutical acceptable carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Examples of pharmaceutically acceptable carriers are magnesium stearate, chalk, starch, lactose, wax, gum or gelatin.
- 10 Carriers which are suited to achieve a sustained release, for example natural or synthetic polymers or liposomes, are known to the one skilled in the art. Pharmaceutically acceptable carriers also comprise liquid carriers and diluents, for example water, alcohol, glycerine or oil, which serve as a
- 15 base for liquid formulations, such as solutions, suspensions or emulsions.

The compositions referred to above may conveniently be presented for use in the form of a pharmaceutical

- 20 formulation and therefore pharmaceutical formulations comprising a composition as defined above together with a pharmaceutically acceptable carrier comprise a further aspect of the invention.
- 25 The individual components of such compositions may be administered either in combination, i.e. simultaneously, or in alternation, i.e. sequentially, in separate or combined pharmaceutical formulations.
- 30 When a compound of the formula (I) is used in combination with a compound of the formula (II) against the same virus the dose of each compound may be either the same as or differ from that

- 17 -

when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

The compositions according to this invention preferably also
5 comprise at least one pharmaceutically acceptable carrier.

According to the third aspect of this invention, the
combination of a compound of the formula (I) and at least one
compound of the formula (II) is used for the manufacture of a
10 medicament for the prophylaxis or the treatment of a viral
infection in a patient.

According to one embodiment, this medicament may be a unit
dosage form, which is preferably useful in combination
15 therapy, such as capsules or tablets. The unit dosage form
contains a pharmaceutical composition according to this
invention, i.e. a compound of the formula (I) in combination
with at least one compound of the formula (II), with at least
one pharmaceutically acceptable carrier.

20

Therefore, another object of this invention also comprises
bringing a compound of the formula (I) and at least a compound
of the formula (II) together in conjunction or association
with a pharmaceutically acceptable carrier.

25

According to another embodiment, this medicament is a multiple
dosage form, preferably a kit of parts, which is especially
useful in alternation and/or combination therapy to flexibly
suit the individual therapeutic needs of the patient.

30

According to one embodiment the combinations, compositions,
kit of parts, manufactures of this invention and the uses

- 18 -

thereof, which comprise a compound of the formula (I) and at least one compound of the formula (II), or a pharmaceutically salt or prodrug thereof, further comprise a further nucleoside reverse transcriptase inhibitor (NRTI), preferably other than
5 3'-deoxy-3'-fluorothymidine.

Following this, a preferred pharmaceutical composition useful for the treatment of viral infections comprises a compound of the formula (I) in combination with 3'-deoxy-3'-fluoro-
10 thymidine and a further NRTI, or a pharmaceutically acceptable salt or prodrug thereof.

Furthermore, a compound of the formula (I) in combination or alternation with preferably 3'-deoxy-3'-fluorothymidine and a
15 further NRTI, or a pharmaceutically acceptable salt or prodrug thereof, is used in the prophylaxis or treatment of a viral infection in a patient.

Also preferred is the use of a compound of the formula (I) in
20 combination with 3'-deoxy-3'-fluorothymidine and a further NRTI, or a pharmaceutically acceptable salt or prodrug thereof, for the manufacture of a medicament for the prophylaxis or treatment of a viral infection in a patient.

25 A preferred kit of parts for the prophylaxis or treatment of a viral infection in a patient, comprises
(a) a first containment containing a pharmaceutical composition comprising a compound of the formula (I) and a pharmaceutically acceptable carrier; and
30 (b) a second containment containing a pharmaceutical composition comprising 3'-deoxy-3'-fluorothymidine and a

- 19 -

further NRTI, or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.

Another preferred kit of parts for the prophylaxis or
5 treatment of a viral infection in a patient, comprises
(a) a first containment containing a pharmaceutical
composition comprising a compound of the formula (I) and a
pharmaceutically acceptable carrier; and

(b) a second containment containing a pharmaceutical
10 composition comprising 3'-deoxy-3'-fluorothymidine, or a
pharmaceutically acceptable salt or prodrug thereof, and a
pharmaceutically acceptable carrier; and
(c) a third containment containing a pharmaceutical
composition comprising a further NRTI, or a pharmaceutically
15 acceptable salt or prodrug thereof, and a pharmaceutically
acceptable carrier.

A preferred manufacture comprises a compound of the formula
(I), 3'-deoxy-3'-fluorothymidine and a further NRTI, or a
20 pharmaceutically acceptable salt or prodrug thereof, for use
in combination or alternation in the prophylaxis or treatment
of a viral infection in patient.

In the foregoing and in the following, the term "a further
25 NRTI" refers to a nucleoside reverse transcriptase inhibitor,
or a pharmaceutically acceptable salt or prodrug thereof,
preferably other than 3'-deoxy-3'-fluorothymidine. Examples of
further NRTIs are AZT, ddI, d4T, ddC, 3TC, FLG, Abacavir,
Emtricitabine, Amdoxovir/DAPD, Ach-126443 and including those
30 NRTIs listed hereinafter. Preferred further NRTI are selected
from the group consisting of AZT, ddI, 3TC, ddC, d4T and FLG,
including its prodrugs. Especially preferred as a further NRTI

- 20 -

is FLG and its prodrugs, in particular those described in WO 99/09031 and WO 99/41268, which documents in their entirety are incorporated herein by reference.

- 5 In a still further embodiment, the pharmaceutical compositions of the present invention may comprise at least one further antiviral agent. The further antiviral agent is preferably chosen from the group consisting of NRTIs (nucleoside-analogue reverse transcriptase inhibitors), NNRTIs (non nucleoside
10 reverse transcriptase inhibitors) and protease inhibitors.

Examples of further antiviral agents are 3TC (lamivudine), AZT (zidovudine), FTC (5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine), d4T (2',3'-dideoxy-2',3'-didehydro-
15 thymidine, stavudine and Zerit), nevirapine, DMP-226, nelfinavir, delavirdine, 9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]guanine, 2-amino-9-[(2-hydroxymethyl)-1,3-dioxolan-4-yl]adenine, MKC-442, 1592U89 (abacavir), 141W94, MK-639, EMS-234475, PNU-140690, ABT-378, DMP-450, Indinavir, saquinavir,
20 tipranavir, ritonavir, efavirenz (sustiva), TIBO, HEPT, BHAP, a-APA, TSAO, calanolides, L-697,661, 2',3'-dideoxycytidine (ddC or zalcitabine), 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine (ddI or didanosine), 3'-deoxythymidine, 2',3'-dideoxy-2',3'-didehydrocytidine, ribavirin, DMP-450 (Triangle
25 Pharmaceuticals, Inc.), 141W94 (amprenavir, GlaxoWellcome, Inc.), Rescriptor (delavirdine), abacavir (1592U89), carbovir, CS-92 (3'-azido-2',3'-dideoxy-5-methyl-cytidine), b-D-dioxolane nucleosides such as b-D-dioxolanylguanine (DXG), b-D-dioxolanyl-2,6-diaminopurine (DAPD), and b-D-dioxolanyl
30 chloropurine (ACP); acyclic nucleosides such as acyclovir, ganciclovir; interferons such as alpha-, beta- and gamma-interferon; glucuronation inhibitors such as probenecid;

- 21 -

nucleoside transport inhibitors such as dipyridamole; immunomodulators such as interleukin II (IL2) and granulocyte macrophage colony stimulating factor (GM-CSF), erythropoietin, ampligen, thymomodulin, thymopentin, foscarnet, glycosylation inhibitors such as 2-deoxy-D-glucose, castanospermine, 1-deoxynojirimycin; and inhibitors of HIV binding to CD4 receptors such as soluble CD4, CD4 fragments, CD4-hybrid molecules and inhibitors of the HIV aspartyl protease such as L-735,524.

10

The further antiviral agent is preferably chosen from zidovudine, didanosine, zalcitabine, stavudine, lamivudine, delavirdine, efavirenz, indinavir, nelfinavir and saquinavir.

- 15 The compounds, or their pharmaceutically acceptable derivative or salts thereof, can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, antiinflammatories, protease inhibitors, or other nucleoside or non-nucleoside antiviral agents, as discussed in more detail above.
- 20

- In general, during alternation therapy, an effective dosage of each agent is administered serially, whereas in combination therapy, an effective dosage of two or more agents are administered together. The dosages will depend on such factors as absorption, biodistribution, metabolism and excretion rates for each drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over
- 25
- 30

- 22 -

time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Examples of suitable dosage ranges for a compound of the formula (I), compounds of
5 formula (II), preferably 3'-deoxy-3'-fluorothymidine, further NRTIs and other antivirals can be found in the scientific literature. Many examples of suitable dosage ranges for other compounds described herein are also found in the public literature or can be identified using known procedures. These
10 dosage ranges can be modified as desired to achieve a desired result.

It has been recognized that drug-resistant variants of HIV can emerge after prolonged treatment with an antiviral agent. Drug
15 resistance most typically occurs by mutation of a gene that encodes for an enzyme used in the viral life cycle, and most typically in the case of HIV, in either the reverse transcriptase or protease genes. It has been demonstrated that the efficacy of a drug against HIV infection can be prolonged,
20 augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, antiviral compound that induces a different mutation(s) from that selected for by the principle drug. Alternatively, the pharmacokinetics, biodistribution, or other parameter of the
25 drug can be altered by such combination or alternation therapy. In general, combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the virus. In the case of administering the antiviral compounds in alternation, i.e.
30 sequentially, the time gap between administering the first compound and the second compound is preferably not too long in

- 23 -

order to achieve a beneficial effect. Preferably, the time gap is less than half a day, most preferably less than 6 hours.

While it is possible that, for use in therapy, a compound
5 of the invention may be administered as the raw chemical
it is preferable to present the active ingredient as a
pharmaceutical formulation. The invention thus further
provides a pharmaceutical formulation comprising a compound of
the formula (I) and a compound of the formula (II) with one or
10 more pharmaceutically acceptable carriers and, optionally,
other therapeutic and/or prophylactic ingredients.

Pharmaceutical formulations include those suitable for
oral, rectal, nasal, topical (including buccal and sub
15 lingual), transdermal, vaginal or parenteral (including
intramuscular, sub-cutaneous and intravenous) administration
in liquid or solid form or in a form suitable for
administration by inhalation or insufflation. The formulations
may, where appropriate, be conveniently presented in discrete
20 dosage units and may be prepared by any of the methods well
known in the art of pharmacy. All methods include the step of
bringing into association the active compound(s) with liquid
carriers or finely divided solid carriers or both and
then, if necessary, shaping the product into the desired
25 formulation.

Pharmaceutical formulation suitable for oral administration
may conveniently be presented as discrete units such as
capsules, including soft gelatin capsules, cachets or tablets
30 each containing a predetermined amount of the active
ingredient(s); as a powder or granules; as a solution, a
suspension or as an emulsion, for example as syrups, elixirs

- 24 -

or self-emulsifying delivery systems (SEDDS). The active ingredient(s) may also be presented as a bolus, electuary or paste. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.

The pharmaceutical composition according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient(s) may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

Pharmaceutical formulations suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories. Suitable

- 25 -

carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound(s) with the softened or melted carrier(s) followed by chilling and
5 shaping in moulds.

When desired the above described formulations adapted to give sustained release of the active ingredient(s) may be employed.

10

The compositions, combinations, kit of parts, manufacture and/or the use of the combinations according to this invention are advantageous in the treatment and/or prophylaxis of viral infections in a patient, preferably human retrovirus (HRV)
15 infections and hepatitis B, in particular HIV infections, especially multiresistant HIV infections. Therefore this invention may offer an aid especially for highly treatment experienced patients suffering from multiresistant HIV. In addition to the treatment of said diseases, the combinations,
20 formulations and compositions according to this invention can be used prophylactically to prevent or retard the progression of clinical illness in individuals who are anti-HIV antibody or HIV-antigen positive or who have been exposed to HIV.

25 The compositions, combinations, kit of parts, manufacture and/or the use of the combinations according to this invention may also be beneficial in preventing perinatal transmission of human retroviral (HRV) infections, in particular HIV-1, from mother to baby. According to this method, a compound of the
30 formula (I) and a compound of the formula (II), preferably 3'-deoxy-3'-fluorothymidine, and optionally further active compounds as described hereinbefore or hereinafter are

- 26 -

administered in combination or alternation to the mother before giving birth.

The compositions, combinations, kit of parts, manufacture
5 and/or the use of the combinations according to this invention may also be beneficial in the treatment and/or prophylaxis of other HIV/AIDS-related conditions such as AIDS-related complex (ARC), persistent generalized lymphadenopathy (PGL), AIDS-related neurological conditions, anti-HIV antibody positive
10 and HIV-positive conditions, Kaposi's sarcoma, thrombocytopenia purpura and opportunistic infections.

Therefore, patients to be treated would be especially those individuals:

- 15 1) infected with one or more strains of a human retrovirus as determined by the presence of either measurable viral antibody or antigen in the serum; and/or
2) in the case of HIV, having either a asymptomatic HIV infection or a symptomatic AIDS defining infection such as i)
20 disseminated histoplasmosis, ii) isopsoriasis, iii) bronchial and pulmonary candidiasis including pneumocystic pneumonia, iv) non-Hodgkin's lymphoma or v) Kaposi's sarcoma and being less than sixty years old; or having an absolute CD4+ lymphocyte count of less than 500/mm³ in the peripheral blood.

25


The pharmaceutical combination according to this invention can be tested for additive and synergistic activity against HIV according to a number of assays known in scientific and public literature, including the one described in the WO 98/44913 and
30 WO 00/51641, which are included herein by way of reference.

- 27 -

Claims:

1. A pharmaceutical composition useful for the treatment or prophylaxis of viral infections comprising a compound of the formula (I)

5



wherein


R² is selected from the group consisting of H, F, Cl, C₁₋₄ alkyl, C₃₋₄ cycloalkyl and CF₃;

10 R⁴ is H or Me;

R⁵ is H, Me or Et,

R¹¹ is Me, Et, cyclopropyl, propyl, isopropyl, or cyclobutyl;


Q is selected from the group consisting of:



15 including a pharmaceutically acceptable salt thereof;

and at least one antiviral active compound of the formula (II)

- 28 -




II

wherein Base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and 2,6-diaminopurine, or a pharmaceutically acceptable salt or
5 prodrug thereof.

2. The pharmaceutical composition according to claim 1 wherein R^2 is Cl, F, or H; R^4 is H; R^5 is Me; R^{11} is Et or

cyclopropyl and Q is



10 3. The pharmaceutical composition according to claim 1 or 2 wherein the compound of the formula (II) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

15 4. The pharmaceutical composition according to one or more of the claims 1 to 3 wherein a compound of the formula (I) and the at least one compound of the formula (II) are present in a synergistic ratio.

20 5. The pharmaceutical composition according to one or more of the claims 1 to 4 wherein a compound of the formula (I) and the at least one compound of the formula (II) are present in a

- 29 -

ratio between about 1:250 to about 250:1.

6. The pharmaceutical composition according to claim 5 wherein a compound of the formula (I) and the at least one compound of the formula (II) are present in a ratio between about 1:50 to about 50:1.

7. The pharmaceutical composition according to one or more of the claims 1 to 6 further comprising a further NRTI, or a pharmaceutically acceptable salt or prodrug thereof.


8. The pharmaceutical composition according to one or more of the claims 1 to 7 with at least one pharmaceutically acceptable carrier.

9. The pharmaceutical composition according to one or more of the claims 1 to 8 for use in the treatment or prophylaxis of human retroviral (HRV) infections.

10. Use of a compound of the formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in combination or alternation with at least one antiviral active compound of the formula (II) according to claim 1, or a pharmaceutically acceptable salt or prodrug thereof, in the prophylaxis or treatment of a viral infection in a patient.

11. The use according to claim 10 wherein R^2 is Cl, F, or H; R^4

is H; R^5 is Me; R^{11} is Et or cyclopropyl and Q is



- 30 -

12. The use according to claim 10 or 11, wherein the compound of the formula (II) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

5 13. The use according to one or more of the claims 10 to 12 in the prophylaxis or treatment of a human retroviral infection (HRV) in a patient.

10 14. The use according to one or more of the claims 10 to 13 in the prophylaxis or treatment of a multiresistant HIV infection in a patient.

15 15. The use according to one or more of the claims 10 to 14 for preventing perinatal transmission of a human retroviral (HRV) infection from mother to baby.

20 16. The use according to one or more of the claims 10 to 15, wherein a compound of the formula (I) and the at least one compound of the formula (II) are administered to the patient in combination or alternation in a synergistic ratio.

25 17. The use according to one or more of the claims 10 to 16, wherein a compound of the formula (I) and the at least one compound of the formula (II) are administered to the patient in combination or alternation in a ratio between about 1:250 to about 250:1.

30 18. The use according to claim 17, wherein a compound of the formula (I) and the at least one compound of the formula (II) are administered to the patient in combination or alternation in a ratio between about 1:50 to about 50:1.


- 31 -

19. The use according to one or more of the claims 10 to 18 in combination or alternation with a further NRTI, or a pharmaceutically acceptable salt or prodrug thereof.

- 5 20. Use of a compound of the formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, in combination with at least one antiviral active compound of the formula
10 (II) according to claim 1, or a pharmaceutically acceptable salt or prodrug thereof, for the manufacture of a medicament for the prophylaxis or treatment of a viral infection in a patient.

21. The use according to claim 20, wherein R^2 is Cl, F, or H; R^4 is H; R^5 is Me; R^{11} is Et or cyclopropyl and

Q is



15

22. The use according to claim 20 or 21, wherein the compound of the formula (II) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

20

23. The use according to one or more of the claims 20 to 22, wherein a compound of the formula (I) is used in combination with said compound of the formula (II) and a further NRTI, or a pharmaceutically acceptable salt or prodrug thereof.

25

24. The use according to one or more of the claims 20 to 23 for the manufacture of a medicament for the prophylaxis or treatment of a human retroviral (HRV) infection in a patient.

- 32 -

25. The use according to one or more of the claims 20 to 24, wherein the medicament is a single dosage form.


- 5 26. The use according to one or more of the claim 20 to 24, wherein the medicament is a multiple dosage form.

27. A kit of parts for the prophylaxis or treatment of a viral infection in a patient, comprising

- 10 (a) a first containment containing a pharmaceutical composition comprising a compound of the formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, and
(b) a second containment containing a pharmaceutical
15 composition comprising an antiviral active compound of the formula (II) according to claim 1, or a pharmaceutically acceptable salt or prodrug thereof, and at least one pharmaceutically acceptable carrier.

- 20 28. The kit of parts according to claim 27, wherein R^2 is Cl, F, or H; R^4 is H; R^5 is Me; R^{11} is Et or cyclopropyl and

Q is



29. The kit of parts according to claim 27 or 28, wherein the
25 compound of the formula (II) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

- 33 -

30. The kit of parts according to one or more of the claims 27 to 29 for use in the prophylaxis or treatment of a human retroviral (HRV) infection in a patient.


5

31. The kit of parts according to one or more of the claim 27 to 30 further comprising a further NRTI, or a pharmaceutically acceptable salt or prodrug thereof.

10 32. A manufacture comprising a compound of the formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one antiviral active compound of the formula (II), or a pharmaceutically acceptable salt or prodrug thereof, for use in combination or alternation in the
15 prophylaxis or treatment of a viral infection in patient.

33. The manufacture according to claim 32, wherein R^2 is Cl, F, or H; R^4 is H; R^5 is Me; R^{11} is Et or cyclopropyl and

Q is



20

34. The manufacture according to claim 32 or 33, wherein the compound of the formula (II) is 3'-deoxy-3'-fluorothymidine, or a pharmaceutically acceptable salt or prodrug thereof.

25 35. The manufacture according to one or more of the claims 32 to 34 for use in combination or alternation in the prophylaxis or treatment of a human retroviral (HRV) infection in patient.


- 34 -

36. The manufacture according to one or more of the claims 32 to 35 further comprising a further NRTI, or a pharmaceutically acceptable salt or prodrug thereof.

- 35 -


Summary

In accordance with the present invention there is provided a pharmaceutical composition useful for the treatment or
5 prophylaxis of viral infections comprising a compound of the formula (I)



wherein R², R⁴, R⁵, R¹¹ and Q are defined as in claim 1;

10 and at least one antiviral active compound of the formula (II)



II

wherein Base is selected from the group consisting of thymine, cytosine, adenine, guanine, inosine, uracil, 5-ethyluracil and
15 2,6-diaminopurine.

THIS PAGE BLANK (USPTO)
